Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-122 in Japanese Subjects With Advanced Solid Tumors or NHL
NCT02509039Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Sep 2015
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avadomide in solid tumor (advanced stage) and non-Hodgkin lymphoma (NHL), sponsored by Celgene Corporation. Started Sep 2015; status: terminated.
02
Drugs
avadomide
03
Conditions
solid tumor (advanced stage)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02509039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509039.